A machine learning enabled drug discovery company developing novel precision immune oncology assets.

Noetik is building a next generation, multiplexed immunohistochemistry platform to identify novel tumor biomarkers from patient samples that can be exploited for therapeutic effect. Noetik is differentiated from other ML-based platform companies in its emphasis on creating a robust, scalable dataset that does not rely on transcriptomics or structural protein models, which have proven challenging to leverage clinically.